{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "1415654",
  "DateCompleted": {
    "Year": "1992",
    "Month": "10",
    "Day": "29"
  },
  "DateRevised": {
    "Year": "2017",
    "Month": "12",
    "Day": "13"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0002-9513",
      "JournalIssue": {
        "Volume": "263",
        "Issue": "3 Pt 2",
        "PubDate": {
          "Year": "1992",
          "Month": "Sep"
        }
      },
      "Title": "The American journal of physiology",
      "ISOAbbreviation": "Am J Physiol"
    },
    "ArticleTitle": "Human IL-1 receptor antagonist partially suppresses LPS fever but not plasma levels of IL-6 in Fischer rats.",
    "Pagination": {
      "StartPage": "R653",
      "EndPage": "R655",
      "MedlinePgn": "R653-5"
    },
    "Abstract": {
      "AbstractText": [
        "A human recombinant interleukin-1 receptor antagonist (IL-1ra) recognizes the two known IL-1 receptors and blocks the binding and many biological effects of both IL-1 alpha and IL-1 beta. The effectiveness of IL-1ra in modifying the fever and plasma IL-6 responses elicited by lipopolysaccharide (LPS) in vivo was tested in Fischer 344 rats. Animals that received IL-1ra 0.5 mg/kg intraperitoneally followed 10 min later by 10 micrograms/kg of LPS displayed significantly lower mean fever responses 2-4 h after injection than rats that received vehicle and LPS (0.48 +/- 0.13 vs. 0.95 +/- 0.16 degrees C, P = 0.016). Plasma levels of IL-6 at 4 h after injection were not different in IL-1ra-treated rats compared with controls (407,725 vs. 729,169 U/ml). Based on our previous finding that preadministration of antiserum to IL-1 beta markedly suppressed plasma IL-6 after LPS, and recent evidence that molar excesses of IL-1ra blocked IL-1-induced circulating IL-6 levels, the possibility that IL-1 is responsible for the induction of bioactive IL-6 during inflammation cannot be ruled out. Similarly, the inability of the IL-1ra to completely suppress the febrile responses of rats to LPS in the present study may be dose related. Alternatively, the induction of bioactive IL-6 by IL-1 in the rat may be mediated primarily through some receptor other than the type I (e.g., the type II receptor)."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "School of Nursing, University of Michigan, Ann Arbor 48109."
          }
        ],
        "LastName": "Smith",
        "ForeName": "B K",
        "Initials": "BK"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kluger",
        "ForeName": "M J",
        "Initials": "MJ"
      }
    ],
    "GrantList": [
      {
        "GrantID": "AI-27556",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "NR-06198-03",
        "Acronym": "NR",
        "Agency": "NINR NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, U.S. Gov't, P.H.S."
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Am J Physiol",
    "NlmUniqueID": "0370511",
    "ISSNLinking": "0002-9513"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "IL1RN protein, human"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Interleukin 1 Receptor Antagonist Protein"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Interleukin-6"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Lipopolysaccharides"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Recombinant Proteins"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Sialoglycoproteins"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Body Temperature"
    },
    {
      "QualifierName": [
        "chemically induced",
        "drug therapy",
        "physiopathology"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Interleukin 1 Receptor Antagonist Protein"
    },
    {
      "QualifierName": [
        "blood"
      ],
      "DescriptorName": "Interleukin-6"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Lipopolysaccharides"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rats"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rats, Inbred F344"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Recombinant Proteins"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Sialoglycoproteins"
    }
  ]
}